A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naïve metastatic castration-resistant prostate cancer.

Enrique Grande,María Piedad Fernández-Pérez,Daniel Wetterskog,Albert Font-Pous,Sergio Vázquez Estévez,Aranzazu Gonzalez del Alba,Begoña Mellado,Ovidio Fernandez Calvo,María José Méndez-Vidal,Miguel Angel Climent,Ignacio Duran,Enrique Gallardo Diaz,Ángel Sánchez,Carmen Santander,M Isabel Sáez,Javier Puente,Elena Castro,Daniel Castellano,Gerhardt Attard,Enrique Gonzalez-Billalabeitia

A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naïve metastatic castration-resistant prostate cancer.

2019

5040Background: TMPRSS2-ERG fusion gene is a common driver of prostate cancer. The PREMIERE study is a phase II, single arm open-label, multicentre, clinical trial designed to analyse the predictiv...

Keywords:

Castration
Prostate cancer
Pathology
Biomarker (medicine)
Oncology
Erg
TMPRSS2
Enzalutamide
Medicine
Internal medicine
Fusion gene
predictive value
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations